|
2010/02/08 AplaGen is proud to be a member of the "Hightech.NRW" consortium focussing on rapid translation of tumor treatment concepts into the clinic. 2010/02/02 Bayer Animal Health and AplaGen sign an evaluation and option agreement 2010/02/01 Medizintechnisches Großprojekt zur schnelleren Entwicklung von neuen Krebsbehandlungsstrategien in Aachen gestartet 2009/12/07 AplaGen announces publication of a patent application for a novel technology that increases half-life of proteins in vivo 2009/11/11 IPI magazine - International Pharmaceutical Industry - publishes an article on Molecular Modelling for Stabilisation of Therapeutic Peptides 2009/08/01 AplaGen presents its major product SESTide at the 2009 Luebeck Conference on EPO as an efficient EPO mimetic substance which, apart from being an agent applicable for fighting anemia, can also be used as an antagonist for (endogenous) EPO in oncological indications 2009/06/01 Wolfgang Oster left the Executive Board 2009/05/29 Article on optimized therapeutic peptides published in the April issue of EBR magazine 2009/03/09 AplaGen participates in the Discovery Summit 2009 in Méridien Beach Plaza, Monaco 2009/01/01 Peter Hillebrandt new member of Executive Board 2008/02/07 New Website online 2008/01/01 New Executive Board 2007/06/29 AplaGen closes financing round
2007/06/15 AplaGen presents HemoMer® at the TIDES, Las Vegas 2006/09/25 Bayer Healthcare AG Animal Health and AplaGen sign a cooperation agreement 2006/02/22 AplaGen GmbH acquires capital to ensure growth chances. 2005/10/29 "Innovationspreis" for AplaGen AplaGen is proud to be a member of the "Hightech.NRW" consortium focussing on rapid translation of tumor treatment concepts into the clinic.
2010/02/08 - Within the “ForSaTum” project, which will focus on new concepts for rapid translation of tumor treatment concepts into the clinic, AplaGen will provide its know how in the development and synthesis of peptides and patented compounds. [download...] Bayer Animal Health and AplaGen sign an evaluation and option agreement
2010/02/02 - AplaGen GmbH and Bayer Animal Health GmbH signed an agreement for the identification and evaluation of a peptide for an undisclosed veterinary indication with a high medical need. The agreement includes an option for Bayer Animal Health to exclusively develop and market the peptide in the animal health field. [download...] Medizintechnisches Großprojekt zur schnelleren Entwicklung von neuen Krebsbehandlungsstrategien in Aachen gestartet
2010/02/01 - Mit dem Jahresbeginn ist der Startschuss für das Kooperationsvorhaben „Forschungssatellit für eine beschleunigte Umsetzung neuer Tumorbehandlungskonzepte (ForSaTum)“ gefallen.
Ziel des Verbundprojektes ist der Aufbau und die Umsetzung eines Versuchskonzeptes zur beschleunigten Umsetzung neuer Tumorbehandlungskonzepte. Die AplaGen GmbH wird in diesem Projekt molekulare Sonden herstellen und produzieren, die für die Verwendung in Tierversuchen gedacht sind.
Das Projekt wird als ein Sieger des Wettbewerbs HighTech.NRW des Ministeriums für Innovation, Wissenschaft, Forschung und Technologie des Landes NRW in einer dreijährigen Laufzeit mit 7,6 Millionen € im Rahmen des EU-NRW Ziel 2-Programms gefördert, 3,6 Millionen € werden von den beteiligten Projektpartnern aufgebracht. [download...] AplaGen announces publication of a patent application for a novel technology that increases half-life of proteins in vivo2009/12/07 - AplaGen GmbH announced today the publication of a patent application describing an innovative formulation allowing elongation of e.g. the half-life of recombinant factor VIII used in hemophilia. This innovative method increases the half-life of complex and/or multifunctional proteins in human and animal circulation, can reduce infusion rates and thereby increase patients quality of life. Aside from the increased quality of life resulting from fewer treatments, it also reduces the cost of the treatment.
Additionally, this non-covalent technology provides the advantage that proteins used in therapy do not have to be chemically modified in order to prolong their half-life. Instead the conjugates are incorporated into the existing pharmaceutical composition in order to exert their function. This also creates a regulatory benefit because there is no change to the active pharmaceutical ingredient (API), only the formulation of the product. [download...] IPI magazine - International Pharmaceutical Industry - publishes an article on Molecular Modelling for Stabilisation of Therapeutic Peptides2009/11/11 - IPI magazine - International Pharmaceutical Industry - publishes an article from Udo Haberl et al. on Molecular Modelling for Stabilisation of Therapeutic Peptides. AplaGen's method of "Isosteric Transformation" is a new and fast molecular modeling procedure enabling structure-based design of D-amino acid based peptides with longer half-life. [download...] AplaGen presents its major product SESTide at the 2009 Luebeck Conference on EPO as an efficient EPO mimetic substance which, apart from being an agent applicable for fighting anemia, can also be used as an antagonist for (endogenous) EPO in oncological indications
2009/08/01 - At the 8th International Luebeck Conference on EPO, AplaGen reported on the present state of its major pharmacological project "SESTide" (supravalent erythropoiesis stimulating peptide). It was shown that SESTide, being a dimeric EPO mimetic peptide (EMP) conjugated to hydroxyethyl starch (HES), shows very competitive efficacy as an erythropoiesis stimulating agent (ESA) both in various in vitro assays and in animal (pharmacodynamic and pharmacokinetic) experiments. Nevertheless, and most remarkably, SESTide and its prototype substance AGEM400(HES) were shown to have a different activity spectrum than recombinant EPO. Whereas AplaGen’s EMP behaves as an effective ESA in in vitro and in in vivo models of erythropoiesis, it was shown to have very poor to absent activity in three leukemic cell lines which respond, by prolonged survival, to recombinant ESA. In one leukemia cell line, UT7, in which the EMP did not show activity at all, the peptide antagonized the survival-promoting effect of EPO by competing for binding to the EPO receptor. In preparation of further studies on the differential effects of recombinant ESA and EMP in other models of malignancies, AplaGen has already filed a patent application on the use of EMP as an agent to be used to antagonize the potentially harmful effects of EPO (endogenous or externally administered recombinant ESA) on malignancies expected to be stimulated by this cytokine (EPO-responsive malignancies). [download presentation...] [download poster...] Wolfgang Oster left the Executive Board2009/06/01 - Last Monday, Wolfgang Oster, MD, Ph.D. left the Executive Board after a very fruitful collaboration over the past 18 months. Wolfgang Oster led AplaGen’s strategic development and prepared the development of its pipeline products for the preclinical phase. He played a significant role in the establishment of AplaGen’s Innovation Partnerships. The company hasn’t yet decided on a replacement for Dr. Oster. Article on optimized therapeutic peptides published in the April issue of EBR magazine2009/05/29
[download...]
AplaGen participates in the Discovery Summit 2009 in Méridien Beach Plaza, Monaco 2009/03/09 - The Discovery Summit 2009 will highlight the industry's current challenges and opportunities on a global level through international keynote presentations and case studies delivered by the most esteemed thought leaders in the industry. To sponsors the Discovery Summit offers the perfect setting to presenct products and services directly to the key decision makers and gate keepers of the immense global R&D budget. Over three days, sponsors will meet and interact with top pharmaceutical and biotechnology executives through a number of business one-to-one meetings and many networking activities. In addition, sponsors will attend the strategic summit sessions led by the thought leaders in the drug discovery community.
[download...] Peter Hillebrandt new member of Executive Board2009/01/01 - On January 1st, 2009 Peter Hillebrandt has officially been appointed as a member of AplaGen’s Executive Board, succeeding Stefan Büchter. Peter Hillebrandt has been Director of NRW.Bank's Equity Finance department and Project Manager since August 2007. As deputy head of Technology and Innovation Finance unit of the bank he is member of the Life Science team and responsible for the MedTech activities. As a member of the Executive Board, Peter Hillebrandt is representing one of AplaGen’s major investors. New Website online2008/02/07 -The newly designed AplaGen website is online. New Executive Board2008/01/01 - In January 2008, AplaGen has newly established an executive board which will assist the executive management team to meet the company´s objectives. The executive board is joined by Stefan Büchter and Dr. Andreas Tietmann as representatives of the investors and Wolfgang Oster, MD, Ph.D.. Wolfgang Oster is an experienced hematologist with an impressing track record in both pharmaceutical industry and venture capital firms. Moreover, he has a long lasting interest in erythropoiesis and was responsible for EPO development at Hoechst/Behring. Wolfgang Oster is chairman of the executive board. Networks and capabilities of this executive board synergize with those of the newly established management team and will help to develop AplaGen to a new and significant player in the field of cytokine pharmacology. AplaGen closes financing round2007/06/29 - The biopharmaceutical company AplaGen GmbH in Baeweiler near Aachen in Germany aquired 3,5 Mio. Euro venture capital for further preclinical development of its peptide products. Investors in this financing round were the present shareholders, lead by Intelligent Venture Capital, Aachen. Further investors are NRW.Bank Venture Fonds, Düsseldorf and as new shareholders KfW and some private investors. In addition to the equity contribution in this financing round the company was able to win significant research grants.
The capital allocation will finance the further preclinical development of AplaGen´s lead product Hemomer®. The patented drug is a fully synthetic EPO mimetic peptide stimulating hematopoiesis in anemia patients. Recombinant drugs already address a 12 b$ market and are prescribed in anemia cases caused by cancer, renal dysfunction or chronic kidney disease. In comparison with the existing recombinant EPO´s Hemomer® offers several advantages for the patients and can be produced very cost efficient. Apart from HemoMer® AplaGen develops with Thrombomer® a closely related Cytokine mimetic peptide. This thrombopoietin mimetic peptide is a stimulator of blood platelet formation in the bone marrow and therefore responsible for bleeding control and coagulation.
AplaGen presents Hemomer® project at the TIDES, Las Vegas 2007/06/15 - AplaGen´s CSO presents the actual stage of the Hemomer® project at the TIDES conference, Las Vegas, USA.
[download...] Bayer Healthcare AG Animal Health and AplaGen sign a cooperation agreement 2006/09/25 - AplaGen GmbH and Bayer HealthCare AG Animal Health have signed an agreement for the evaluation, development and marketing of several therapeutic peptides from the AplaGen pipeline. The peptides will be used in the veterinary field only.
[download...] AplaGen GmbH acquires capital to ensure growth chances. 2006-02-22 - NRW.Bank and IVC enlarge their former engagement.
[download...] "Innovationspreis" for AplaGen 2005/10/29 - The "Innovationspreis der StädteRegion Aachen" was awarded to AplaGen GmbH. This innovation prize is an award for outstanding corporate and scientific achievement.
[download...] |
